Recent News

• 07.31.2025 - LakeShore Biopharma Announces Fiscal Year 2025 Financial Results
• 07.08.2025 - LakeShore Biopharma Announces US$15 Million Private Placement Financing
• 04.23.2025 - LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
• 12.19.2024 - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
• 12.13.2024 - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
• 12.13.2024 - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

Recent Filings

• 07.22.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 07.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 07.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.08.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.14.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 03.12.2025 - EX-99.1 EX-99.1